Stockscreener 앱 받기
34.74
0.12%
0.04
시간 외 거래:
34.74
전일 마감가:
$34.70
열려 있는:
$39.37
하루 거래량:
937.64K
Relative Volume:
2.39
시가총액:
$1.91B
수익:
$597.40M
순이익/손실:
$-15.51M
주가수익비율:
47.59
EPS:
0.73
순현금흐름:
$99.84M
1주 성능:
+1.05%
1개월 성능:
+8.49%
6개월 성능:
+12.68%
1년 성능:
+41.91%
1일 변동 폭
$33.43
$39.37
1주일 범위
$33.43
$39.37
52주 변동 폭
$23.05
$39.37
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-03 | 재개 | Jefferies | Buy |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 재개 | Jefferies | Hold |
| 2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-11-12 | 재확인 | B. Riley FBR | Buy |
| 2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
| 2017-10-19 | 개시 | FBR & Co. | Buy |
| 2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 개시 | Janney | Neutral |
| 2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2015-11-05 | 재확인 | Northland Capital | Outperform |
| 2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Earnings call: Supernus Pharmaceuticals reported a significant increase in total revenue - Investing.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High Following Earnings Beat - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highli - GuruFocus.com
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates - MSN
Supernus Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Supernus Pharmaceuticals Q3 2024 Earnings: EPS of $0.69 Beats Es - GuruFocus.com
Supernus Announces Third Quarter 2024 Financial Results - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results - MarketBeat
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals (FRA:S49) PE Ratio : 387.50 (As of Nov. 04, 2024) - GuruFocus.com
Supernus: Q3 Earnings Snapshot - The Washington Post
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
(SUPN) On The My Stocks Page - Stock Traders Daily
Macquarie Group Ltd Adjusts Stake in Supernus Pharmaceuticals Inc - GuruFocus.com
Stephens Investment Management Group LLC Buys 33,710 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Dimensional Fund Advisors LP Expands Stake in Supernus Pharmaceu - GuruFocus.com
Supernus Presents Promising Data from Open-Label Phase 2a - GlobeNewswire
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - Yahoo Finance
Supernus Pharmaceuticals reports rapid depression treatment response By Investing.com - Investing.com Australia
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk - Simply Wall St
Supernus Pharmaceuticals reports rapid depression treatment response - Investing.com India
Supernus Pharmaceuticals (SUPN) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
Attention Deficit Hyperactivity Disorder Market Projected - openPR
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results - The Manila Times
Supernus Pharmaceuticals to Host Conference Call and - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 12-Month HighTime to Buy? - MarketBeat
Exchange Traded Concepts LLC Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus’ depression drug improved symptoms in two hours in Phase IIa study - Clinical Trials Arena
Supernus stock holds Buy rating on MDD trial data By Investing.com - Investing.com UK
Supernus Announces Promising Data from Open-Label Phase 2a - GlobeNewswire
Supernus reports Phase 2a data for SPN-820, stock climbs 6% - MSN
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with - The Bakersfield Californian
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder - StockTitan
SUPN (Supernus Pharmaceuticals) 3-Year EPS without NRI Grow - GuruFocus.com
(SUPN) Trading Signals - Stock Traders Daily
Millennium Management LLC Buys 128,743 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder - The Manila Times
Supernus Pharmaceuticals to Host Webcast to Review - GlobeNewswire
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Healthcare of Ontario Pension Plan Trust Fund Buys Shares of 40,000 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Marshall Wace LLP Acquires Shares of 73,519 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
(SUPN) Technical Data - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Bank of Montreal Can - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Armistice Capital LLC Has $141.03 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Pulling back 3.6% this week, Supernus Pharmaceuticals' NASDAQ:SUPN) five-year decline in earnings may be coming into investors focus - Simply Wall St
Busy Philipps Encourages Women to Take Charge of Their ADHD - GlobeNewswire
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Supernus Pharmaceuticals Inc 주식 (SUPN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GEMAYEL GEORGES | Director |
Sep 13 '24 |
Sale |
31.33 |
13,886 |
435,048 |
13,315 |
0.88%
0.42%
자본화:
|
볼륨(24시간):